Expert Ratings For Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Apellis Pharmaceuticals (NASDAQ:APLS) has received diverse analyst ratings over the past quarter, with a total of 14 analysts offering opinions ranging from bullish to bearish. The recent ratings show a shift towards more positive sentiment in the last 30 days. The 12-month price targets for APLS have an average of $79.43, with a high of $92.00 and a low of $60.00, marking a 13.47% increase from the previous average target of $70.00. Analysts have maintained or raised their ratings and price targets, reflecting changing market dynamics and Apellis Pharmaceuticals' performance. The company, a commercial-stage biopharmaceutical entity, focuses on novel therapies for diseases with high unmet needs. Despite its exceptional revenue growth rate of 545.89% over the past 3 months and a strong net margin of -60.51%, Apellis faces challenges with below-industry-average ROE and ROA, and a prudent debt management strategy with a debt-to-equity ratio of 0.57.

April 15, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals has seen a positive shift in analyst sentiment with an increased average price target of $79.43, reflecting optimism in its stock potential. The company's significant revenue growth and strategic financial management are key highlights, despite some operational challenges.
The positive shift in analyst sentiment, evidenced by the increased average price target and the maintenance or upgrading of ratings, suggests a bullish outlook for APLS in the short term. The company's impressive revenue growth rate and its strategic approach to managing debt highlight its potential for growth and stability, despite the challenges in ROE and ROA. These factors contribute to a positive impact on APLS's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100